• search
Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Intermediates and API Contract Manufacturing Services

Intermediates and API Contract Manufacturing Services

Long-term partner to support your commercial product through its market lifecycle.

Aurigene has a legacy of developing 500+ molecules, several of which are in the commercial phase in highly regulated markets such as the USA, Europe, Japan, etc. We support our customers at various stages of a late-phase product from regulatory filing to launch and at the patent expiry stage with cost optimization options. Our vast manufacturing footprint allows us the flexibility to choose from a variety of unit operations suitable for product manufacturing. Our expertise in regulatory filings and documents will help our customers create comprehensive documentation for NDA and other global regulatory filings.  

We offer a wide range of manufacturing services from a few kilos to multi tons of cGMP manufacturing of Key Starting Material (KSM) / Registered Starting Materials (RSM), advanced intermediates, and APIs. Our facilities can handle a diverse set of chemical reactions at various scales. Our facilities are inspected by global regulatory authorities like the US FDA, UK MHRA, TGA Australia, PMDA Japan, and other regulatory agencies. Our facilities can handle the manufacturing of niche technologies like peptides, High Potent Active Pharmaceutical Ingredients (HPAPIs), steroids, Methoxy Polyethylene Glycols (m-PEGs), and prostaglandins. Our state-of-the-art facilities are located across the globe in India, the UK, and Mexico.

Speak to our experts

cGMP Manufacturing Scale

Reactor size

  • Kilo lab: 50 to 630 L
  • Commercial: 500 to 10,000 L

Capacity of Production

  • Kilo lab: 1 to 10 Kg
  • Commercial: 15 to 500 Kg

MOC

  • All glass set-up, Mild Steel Glass Lined (MSGL), stainless steel (SS316), and Hastelloy

Niche reactions

  • Cryogenic reactor size (2,000 to 11,000 L) with Reaction temperature up to -80 deg C
  • Hydrogenator capacity (20 to 5000 L) at 4 to 3535 bars

Downstream Operations

Centrifuge

  • 12”, 36” and 48”

Nustche Filters

  • 25 L to 1 KL

Agitated Nustche Filter Dryer (ANFD)

  • 0.1 m2 to 5.0 m2

Spray Dryers

  • 5 to 50 Kg/Hr

Micronization

  • Development (M50)
  • Manufacturing (M100 to M2000

All manufacturing facilities are equipped with particle size regulating equipment including multi-mill, air jet mill or micronizer, sifter, and blenders. Dedicated unit for the micronization of steroid products. Steroid manufacturing facility is also equipped with micronizer.

Steroid

Development/PoC

  • Quantity: 10 to 50 g
  • Capacity: Lab scale

Pre-clinical or Non GMP

  • Quantity: 100 to 250 g
  • Capacity: 20 to 50 L

Early Phase

  • Quantity: 1 to 3 kg
  • Capacity: 20 to 189 L

Late Phase

  • Quantity: 5 to 10 Kg
  • Capacity: Up to 7,000 L

Commercial

  • Quantity: 25 to 100 Kg
  • Capacity: Up to 7,000 L

HPAPI

Development/PoC/Non GMP

  • Quantity: 10 to 50 g
  • Capacity: Lab scale

Pre-clinical

  • Quantity: 100 to 250 g
  • Capacity: Lab scale

Early Phase

  • Quantity: 1 to 3 kg
  • Capacity: ~20 to 2,000 L

Late Phase

  • Quantity: 5 to 10 Kg
  • Capacity: 160 to 2,000 L

Commercial

  • Quantity: 10 to 15 Kg
  • Capacity: 160 to 2,000 L

PEGylation

Development/PoC

  • Quantity: 10 to 50 g
  • Capacity: Lab scale

Pre-clinical/NGMP

  • Quantity: 250 to 500 g
  • Capacity: Lab scale

Early Phase

  • Quantity: 25 to 50 kg
  • Capacity: 50 to 3,000 L

Late Phase

  • Quantity: 100 to 250 Kg
  • Capacity: 50 to 3,000 L

Commercial

  • Quantity: 500 to 1,000 Kg
  • Capacity: 50 to 3,000 L

Carbohydrate

Development/PoC

  • Quantity: Up to 100 g/batch
  • Capacity: Lab scale

Commercial

  • Quantity: Up to ~30 Kg/batch
  • Capacity: 60 to 250 L

Purification: GPC technique, size-exclusion chromatography, SAX purification, Ion-exchange chromatography

Analytical Capability at The Plant

Chromatography

  • HPLC (UV, PDA, ELSD & RI detectors with Empower 3 software)
  • GC (FID, TCD, ECD detectors with Empower 3 software)
  • UPLC instruments

Characterization

  • Mass spectrometer (LC-MS & HR-MS)
  • AB SCIEX 4500 QQQ instrument
  • Waters UPLC with LCT premier XE time of flight detector
  • Agilent HPLC with 6410 triple quad mass detector
  • Agilent GC with 5975C EI/CI Inert XL detector

Spectroscopy and Thermal analysis

  • UV-Vis, IR, NMR spectroscopy, and photometers
  • DSC and TGA
  • Surface area analyzers

Sustainable Manufacturing

Sustainability is one of our core values and we continue to build on our goals aligned with global standards. Our work in the field of sustainability was recognized by:

  • DJSI (Dow Jones Sustainability Indices)
  • FTSE4Good Index
  • CDP (Carbon Disclosure Project)
  • S&P BSE Carbonex
  • S&P BSE Greenex
  • Bloomberg Gender-Equality Index
  • CII-SR EHS Excellence Silver Award
  • PSCI Audited

Regulatory

Our development center is a US FDA audited facility, and our manufacturing plants are regularly audited by the US FDA, EDQM, KFDA (Korea), MHRA (UK), PMDA, SFDA, CDSCO, DMA, TGA, WHO GMP, and COFEPRIS.

Why Aurigene Pharmaceutical Services?

US FDA Inspected Labs

Integrated Development and Manufacturing

25 to 50 gms per batch

Dedicated Analytical Lab

Virtual Tour

 

Contact Us

Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
resourceMainImage

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More
resourceMainImage

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More
resourceMainImage

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug

2023

Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack